⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INVA News
Innoviva, Inc. Common Stock
Innovaccer Launches Galaxy UM to Transform Utilization Management with AI-Powered Automation
businesswire.com
INVA
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report
businesswire.com
INVA
Innovaccer Receives Frost & Sullivan's 2026 United States New Product Innovation Recognition for Excellence in AI-Driven Patient Access Solutions
prnewswire.com
INVA
Form 8-K
sec.gov
INVA
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
businesswire.com
INVA
Innoviva to Participate in the Oppenheimer 36 th Annual Healthcare Life Sciences Conference
businesswire.com
INVA
62% of Healthcare Leaders Say Fragmented Data Is Blocking AI Scale, New Innovaccer Report Finds
businesswire.com
INVA
Ash Partners with Innovaccer to Bring At-Home Care Delivery Infrastructure into AI-Powered Galaxy Platform
businesswire.com
INVA
U.S. FDA Approves NUZOLVENCE ® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
businesswire.com
INVA
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
businesswire.com
INVA